Thailand's Pharmaceutical Cold Chain Market Is Growing Fast: What It Means for Regulated Importers

Thailand's pharmaceutical cold chain infrastructure has expanded significantly over the past three years, driven by post-pandemic investment in healthcare supply chain resilience, growing medical cannabis export volumes, and increasing demand from multinational pharmaceutical manufacturers seeking Southeast Asian regional distribution hubs. For regulated importers sourcing products from Thailand or distributing into the Thai market, the question has shifted from whether GDP-compliant cold chain partners exist to how to identify and qualify the right ones.

Market Size and Growth Context

Thailand's broader cold chain logistics market is valued at USD 2.4 billion in 2026, according to Mordor Intelligence, with a projected CAGR of 3.79% through 2031. Pharmaceuticals and biologics represent the fastest-growing application segment within that total, projected at a 5.88% CAGR through 2031 (Mordor Intelligence). Separately, Ken Research estimates that approximately one third of Thailand's pharmaceutical portfolio requires compliant cold chain handling. These figures reflect the total cold chain market across all sectors — food, pharmaceutical, and other temperature-sensitive cargo — not a pharmaceutical-specific figure. The pharmaceutical segment is growing faster than the overall market, driven by GDP mandate enforcement by the Thai FDA and increasing import volumes of biologics and specialty medicines requiring 2 to 8°C or ultra-cold handling.

What Has Changed in the Infrastructure Landscape

Three years ago, GDP-compliant pharmaceutical cold chain in Thailand was largely the domain of a small number of specialist providers with deep pharmaceutical expertise and premium pricing. The market has matured substantially. Cold chain warehousing with pharmaceutical-grade temperature zones (2 to 8°C, 15 to 25°C, and minus 20°C) is now available from multiple providers at competitive pricing. IATA-certified pharmaceutical packaging is available locally. Freight forwarding with pharmaceutical-specific expertise and experience handling controlled substances including medical cannabis is no longer rare. The Thai FDA's enforcement of GDP requirements from 2022 onwards has driven investment in validated equipment, temperature mapping, and digital environmental monitoring across the sector.

What This Means for Regulated Importers

Improved infrastructure means that supply chain quality is increasingly a function of operational discipline rather than infrastructure scarcity. The relevant questions to ask a Thai supplier or logistics partner are now: Do they have documented and validated SOPs for cold chain handling? Are their staff trained to GDP standards with records to demonstrate it? Do they use calibrated, certified temperature monitoring devices with factory-issued calibration certificates? Can they produce complete GDP shipment documentation packages — pre-shipment quality records, logger calibration certificates, transit temperature reports, and post-delivery disposition records — that would satisfy a quality team's supplier audit? The answer to all of these questions should be yes before any commercial relationship is established.

DeeMED's Logistics Infrastructure

DeeMED's logistics operations for medical cannabis and pharmaceutical exports are supported by a global freight partner operating across more than 50 countries, with more than 300 offices and over 7,500 staff globally. For medical cannabis shipments specifically, DeeMED manages the complete export logistics package: GDP-compliant cold chain with Frigga V5 Core single-use data logger deployment, INCB documentation coordination, ONCB export authorization management, and full chain-of-custody documentation from the Thai facility to the destination importer's dock. For imported pharmaceutical products into Thailand, DeeMED supports logistics coordination and GDP documentation management through the same infrastructure.